金刚娱乐app官网最新版【安卓版/IOS】

Transcenta, Biologics, Antibody, Claudin 18.2

金刚娱乐app官网最新版【安卓版/IOS】丨页面结构与功能概览

Careers Contact
English
简体 English 繁体

Latest News

Press Release
2025-12-29
Transcenta Therapeutics Announces Strategic Collaboration and Non-exclusive Licensing Agreement to Advance Integrated Continuous Biomanufacturing and Expand Global Access to Affordable Biologics
2025-12-05
Transcenta Therapeutics Presents Updated Efficacy Data from the Phase I/II Transtar102 Trial of Osemitamab plus Nivolumab and CAPOX in First-line G/GEJ Cancer at ESMO Asia
2025-10-31
Transcenta’s Partner Inhibrx Reports Positive Phase 2 Results for Ozekibart in Chondrosarcoma, with a BLA Submission Planned for 2026
More More
Events
2025-11-28
Transcenta to Present Updated Efficacy Analysis from a Phase I/II Study of First-line Osemitamab (TST001) plus Nivolumab and CAPOX for Advanced G/GEJ Cancer at ESMO Asia
2025-11-26
Bioprocess Summit: Intensified and Continuous Bioprocessing-Driving Efficiency, Cost, and Sustainability
More More


Innovation

Discovery

Employing a unique antibody generation platform based on Immune Tolerance Breaking Technology to generate therapeutic candidate leads with differentiated biological profile and enhanced druggability attributes.

Translational Research

Our translational research generates PK, PD, Tox and immunogenicity data through validated quantitative platforms, and enables us to model clinical responses to our investigational agents for better understanding of PK/PD/Safety profiles, which guides design and conduct of clinical studies.

Process Development

We can leverage both classical fed-batch and perfusion-based continuous bioprocessing technologies to enable fast-to-IND and fast-to-market process development.

Clinical Development

Based in Beijing, Shanghai, Guangzhou and Princeton, US, our teams at global clinical development centers and regulatory teams have extensive knowledge and experience in designing and executing clinical trials at all stages.

Manufacturing

Equipped with a flexible modular manufacturing facility and advanced next-generation perfusion bioprocessing platform, we are able to significantly accelerate process development and reduce the cost of manufacturing.

Partnering

Benefited from the global network and industry resources of our prominent shareholders with deep biotech expertise, we have forged multiple forms of important strategic cooperation with leading domestic and international pharmaceutical companies and equipment suppliers.

2012
Company Established
139
Issued & Pending Patents
16
Pipeline
2021
Listed in HKEX
7
Global Footprints